![](/img/no_image.jpg)
- /
- Supported exchanges /
- SHG /
- 688062.SHG
Mabwell (Shanghai) Bioscience Co. Ltd. A (688062 SHG) stock market data APIs
Mabwell (Shanghai) Bioscience Co. Ltd. A Financial Data Overview
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products in China and internationally. The company offers its products for oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection; MAILISHU for the treatment of postmenopausal women with osteoporosis; JUNMAIKANG, an immunological product; and MAIWEIJIAN for giant cell tumor of bone. The company's oncology products pipeline includes 9MW2821 which is in phase III clinical trial; 6MW3211, which is in phase II of clinical trial; 6MW3211 which is in phase II clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; and 8MW0511, which has completed phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; hematology product comprising 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is headquartered in Shanghai, China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Mabwell (Shanghai) Bioscience Co. Ltd. A data using free add-ons & libraries
Get Mabwell (Shanghai) Bioscience Co. Ltd. A Fundamental Data
Mabwell (Shanghai) Bioscience Co. Ltd. A Fundamental data includes:
- Net Revenue: 169 M
- EBITDA: -1 017 080 768
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-03-31
- EPS/Forecast: NaN
Get Mabwell (Shanghai) Bioscience Co. Ltd. A End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mabwell (Shanghai) Bioscience Co. Ltd. A News
![Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation](/img/newsCloud/fallback3.jpg)
Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation
SHANGHAI, Jan. 9, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ...
![](/img/no_image.jpg)
![Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA](/img/newsCloud/fallback7.jpg)
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA
SHANGHAI, Nov. 14, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has...
![Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference](/img/newsCloud/fallback9.jpg)
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-ba...
![Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor](/img/newsCloud/fallback5.jpg)
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor
SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) o...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.